Viewing Study NCT03852251


Ignite Creation Date: 2025-12-24 @ 11:57 PM
Ignite Modification Date: 2026-01-03 @ 6:44 PM
Study NCT ID: NCT03852251
Status: COMPLETED
Last Update Posted: 2024-08-02
First Post: 2019-02-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma
Sponsor: Akeso
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module